In addition to being useful in the diagnosis of individuals presenting with unusual manifestations of preeclampsia, we suggest that these two biomarkers and the sFlt-1/PIGF ratio may also be useful in predicting preeclampsia in chronically hypertensive women at risk of developing superimposed preeclampsia.44One crucial component in the therapeutic treatment of preeclampsia is placental induced growth factor (PIGF). This evidence concerns the gene PIGF and preeclampsia.